Outcomes After Left Main Coronary Artery Revascularization by Percutaneous Coronary Intervention or Coronary Artery

Bahira Shahim1, Björn Redfors2, Shmuel Chen3

  • 1Clinical Trials Center, Cardiovascular Research Foundation, New York, New York.

Insights

Current smokers undergoing revascularization for left main coronary artery disease (LMCAD) face a higher risk of adverse outcomes. Former smokers showed no increased risk, and treatment effectiveness was similar regardless of smoking status.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Clinical Trials

Background:

  • Cigarette smoking is a known risk factor for coronary artery disease (CAD).
  • The impact of smoking on outcomes after coronary revascularization in patients with left main CAD (LMCAD) requires further investigation.

Purpose of the Study:

  • To evaluate the 5-year outcomes of patients with LMCAD based on smoking status after percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG).

Main Methods:

  • The EXCEL trial randomized 1,905 patients with LMCAD to PCI or CABG.
  • Patients were stratified into current, former, and never smokers.
  • Outcomes were compared using logistic regression, with follow-up time as a log-transformed offset variable.

Main Results:

  • Among 1893 patients, 22% were current smokers and 41% were former smokers.
  • Current smokers had a significantly higher adjusted risk of the primary composite endpoint (death, myocardial infarction, stroke) compared to never smokers (adjOR 1.82).
  • Former smokers did not show an increased risk (adjOR 1.00), and the efficacy of PCI versus CABG was similar across smoking groups.

Conclusions:

  • Current smoking is an independent risk factor for adverse outcomes after LMCAD revascularization.
  • Former smoking status does not confer an increased risk.
  • Revascularization strategy (PCI vs. CABG) showed similar efficacy irrespective of smoking status.

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
174
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
186
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
530
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
164
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
289
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
176